![William James Jonathan Finlay](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van William James Jonathan Finlay
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
UltraHuman Ltd.
![]() UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met William James Jonathan Finlay via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Medicxi Ventures (Jersey) Ltd.
![]() Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder Founder Private Equity Investor | |
Impact Biomedicines, Inc.
![]() Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member Director/Board Member | |
Index Ventures (UK) LLP | Investment Managers | Private Equity Investor Private Equity Investor | |
MOLECULAR PARTNERS AG | Biotechnology | Director/Board Member Director/Board Member | |
Xenikos BV
![]() Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member Director/Board Member | |
Levicept Ltd.
![]() Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Chairman Director/Board Member | |
Rivus Pharmaceuticals, Inc.
![]() Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Pharmaceuticals: Major | Director/Board Member | |
SDS Therapeutics Ltd.
![]() SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member | |
CENTESSA PHARMACEUTICALS PLC | Pharmaceuticals: Major | Chairman | |
ADDEX THERAPEUTICS LTD | Pharmaceuticals: Major | Director/Board Member | |
Orexia Therapeutics Ltd.
![]() Orexia Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
ZYLA LIFE SCIENCES | Pharmaceuticals: Major | Director/Board Member | |
GENMAB A/S | Pharmaceuticals: Major | Director/Board Member | |
MINERVA NEUROSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Egalet A/S
![]() Egalet A/S Pharmaceuticals: MajorHealth Technology Egalet A/S operates as a specialty pharmaceuticals company. It develops opioid formulations for pain management based on abuse deterrent prolonged release erosion matrix technology in Denmark. The company develops prolonged and delayed release therapeutics for chronic pain management, including Parvulet, a delivery platform for facilitating dispensing of oral doses to pediatric and geriatric patient segments; and Egalet morphine. The company was founded by Jan Quistgaard in 1995 and is headquartered in Vaerloese, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Synox Therapeutics Ltd.
![]() Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Critical Pressure Ltd.
![]() Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Index Ventures SA
![]() Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Private Equity Investor | |
Egalet Ltd.
![]() Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
PHATHOM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Palladio Biosciences, Inc.
![]() Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member | |
Z Factor Ltd.
![]() Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Biotechnology | Director/Board Member | |
Breakpoint Therapeutics GmbH
![]() Breakpoint Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breakpoint Therapeutics GmbH engages in the discovery and development of anti-cancer drugs. It aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. The company is headquartered in Hamburg, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Sydnexis, Inc.
![]() Sydnexis, Inc. Pharmaceuticals: MajorHealth Technology Sydnexis, Inc. engages in the production of ophthalmic pharmaceutical products. The company was founded by Gregory Isaac Ostrow in 2014 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member | |
The University of North Carolina at Chapel Hill | College/University | Doctorate Degree | |
Bioqube Ventures NV | Investment Managers | Private Equity Investor | |
CodeBase Ltd.
![]() CodeBase Ltd. Information Technology ServicesTechnology Services Codebase Ltd. provides technology incubator services. The company was founded by Jamie Coleman and Stephen Coleman in November 21, 2012 and is headquartered in Edinburgh, the United Kingdom. | Information Technology Services | Founder | |
Creative Industries Federation
![]() Creative Industries Federation Miscellaneous Commercial ServicesCommercial Services Creative Industries Federation operates as membership organization. The company was founded in 2014 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Sequenta, Inc.
![]() Sequenta, Inc. BiotechnologyHealth Technology Sequenta, Inc. operates as a biotech company which discovers and develops clinical diagnostics based on immune system status. It develops molecular diagnostic assays based on a sequencing approach to the profiling of T and B cell receptor repertoires. The firm also provides sequencing-based test for minimal residual disease for leukemia and lymphoma. The company was founded by Thomas D. Willis and Malek Faham in 2007 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
Morphogen-IX Ltd.
![]() Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
University of Cambridge | College/University | Doctorate Degree | |
University of Melbourne
![]() University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | College/University | Corporate Officer/Principal | |
MedImmune Ltd.
![]() MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Corporate Officer/Principal | |
The University of Edinburgh | College/University | Undergraduate Degree | |
ACUTUS MEDICAL, INC. | Medical Specialties | Director/Board Member | |
Inhibitaxin Ltd.
![]() Inhibitaxin Ltd. BiotechnologyHealth Technology Inhibitaxin Ltd. engages in research and development on biotechnology. The company was founded by Simon Lempriere Westbrook and Kevin S. Johnson in 2013 and is headquartered in Kent, the United Kingodm. | Biotechnology | Founder | |
ApcinteX Ltd.
![]() ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Capella Bioscience Ltd.
![]() Capella Bioscience Ltd. Pharmaceuticals: MajorHealth Technology Capella Bioscience Ltd. develops medicines based on monoclonal antibodies to the next generation therapeutic targets in oncology and autoimmune disease. The company was founded by Steve Holmes in 2014 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Stealthyx Therapeutics Ltd.
![]() Stealthyx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Stealthyx Therapeutics Ltd. operates drug delivery system technology. The company was founded by Yuti Chernajovsky and Eileen Janis Anderson in 2002 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Rebalance (Cambridge) Ltd.
![]() Rebalance (Cambridge) Ltd. Miscellaneous Commercial ServicesCommercial Services Rebalance (Cambridge) Ltd. provides research and experimental development on biotechnology. The company was founded on December 6, 2016 and is headquartered in Hatfield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
ProFibrix BV
![]() ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
Verenigd Koninkrijk | 23 |
Verenigde Staten | 15 |
Zwitserland | 5 |
Nederland | 4 |
Denemarken | 3 |
Sectoraal
Health Technology | 36 |
Commercial Services | 7 |
Finance | 5 |
Consumer Services | 5 |
Technology Services | 2 |
Operationeel
Director/Board Member | 54 |
Private Equity Investor | 7 |
Corporate Officer/Principal | 7 |
Founder | 6 |
Independent Dir/Board Member | 5 |
Sterkste connecties
Insiders | |
---|---|
Francesco de Rubertis | 36 |
Kevin Johnson | 22 |
Jonathan Edwards | 12 |
James Edward Coleman | 4 |
Jonny Finlay | 1 |
- Beurs
- Insiders
- William James Jonathan Finlay
- Bedrijfsconnecties